Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001062287 - METHODS OF PREVENTION AND TREATMENT OF ASTHMA, AND ALLERGIC CONDITIONS

Publication Number WO/2001/062287
Publication Date 30.08.2001
International Application No. PCT/US2001/005660
International Filing Date 23.02.2001
Chapter 2 Demand Filed 31.08.2001
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 38/19 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 16/24 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/42 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42against immunoglobulins (anti-idiotypic antibodies)
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 38/177
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
A61K 38/1774
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
A61K 38/1793
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1793for cytokines; for lymphokines; for interferons
A61K 38/1796
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1796for hormones
Applicants
  • ADVANCED BIOTHERAPY, INC. [US]/[US]
Inventors
  • SUKURKOVICH, Boris
  • SKURKOVICH, Simon
Agents
  • DOYLE, Kathryn
Priority Data
09/511,97224.02.2000US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF PREVENTION AND TREATMENT OF ASTHMA, AND ALLERGIC CONDITIONS
(FR) METHODES DE PREVENTION ET TRAITEMENT DE L'ASTHME ET D'ETATS ALLERGIQUES
Abstract
(EN) The present invention relates to allergy vaccines and methods of treating and/or preventing asthma, and allergic conditions. The invention is based on the discovery that inhibiting the ligand/receptor interactions involving, e.g., IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interferon-alpha, histamine, leukotriene, and their respective receptors, inhibits production of IgE thereby treating or preventing such diseases or conditions. Competitive inhibition of such receptor/ligand interactions is accomplished by immunizing a human or veterinary patient with the interleukin, interferon-alpha, histamine, leukotriene, their receptors, in any combination. Also, the invention relates to inhibiting receptor/ligand interactions involved in IgE production by competitively inhibiting such interactions by administering antibodies to the ligands, receptors, or both, as well as by administering analogs of the receptors (e.g.), soluble receptors not associated with a cell).
(FR) L'invention porte sur des vaccins anti-allergiques, et sur des méthodes de traitement et/ou prévention de l'asthme et d'état allergiques, se basant sur la découverte qu'en inhibant les interactions ligand/récepteur, par exemple: IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interféron-alpha, histamine, leucotriène, et leurs récepteurs respectifs, on inhibait la production d'IgE, et traitait par là les maladies et états en question. L'inhibition compétitive de ces interactions ligand/récepteur se fait en immunisant un humain ou un animal avec de l'interleukine, de interféron-alpha, de l'histamine, de la leucotriène, leurs récepteurs ou leurs combinaisons. L'invention porte également sur l'inhibition compétitive des interactions ligand/récepteur, due à la production d'IgE par administration d'anticorps aux ligands, aux récepteurs ou aux deux, ou par administration d'analogues des récepteurs (par exemple des récepteurs solubles non associés à une cellule).
Latest bibliographic data on file with the International Bureau